This week's biotech landscape witnessed key FDA approvals, EU approvals, IND clearances, acquisitions, and clinical trial data readouts across key therapeutic areas such ...

The FDA has approved Johnson & Johnson’s Tecvayli plus Darzalex Faspro for adults with relapsed or refractory multiple myeloma following one to three prior therapies, including a proteasome inhibitor ...

The collaboration will make facility-level flexibility a standard capability across every InfraPartners AI data center ...

Johnson & Johnson (NYSE:JNJ) received FDA Fast Track designation for nipocalimab as a potential treatment for systemic lupus erythematosus, supported by positive Phase 2 data and the start of a Phase ...

Bristol Myers Squibb and Johnson & Johnson have begun an educational campaign about the factor XIa pathway, laying the groundwork for a launch that could follow phase 3 readouts expected this year.

Nvidia's next-generation AI infrastructure operates in a way that could potentially drive demand for Johnson Controls' products. Data centers' infrastructure is not Johnson Controls' core business, ...

The "Biological Therapies for Cancer: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering.

CORK, Ireland—Johnson Controls delivered robust financial results for fiscal year 2025 while laying out the foundation for a transformation that blends operational discipline with cutting-edge ...

Johnson Controls delivered a strong Q4, surpassing expectations and prompting a rating upgrade from Hold to Buy with a $125 target price. JCI's transformation, backlog growth, margin improvement, and ...

Add Yahoo as a preferred source to see more of our stories on Google. BMS and Johnson & Johnson said the IDMC does not believe the ACS trial will meet its primary endpoint. Image credit: Piyaset / ...